Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

1.7K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.7K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

1.5K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.5K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current perspectives on β<sub>2</sub>-adrenergic receptor agonists in asthma: navigating from track to track within GINA recommendations.

Expert opinion on pharmacotherapy·2026
Same author

Real-World Effectiveness and Safety of Extrafine Triple Therapy in COPD Patients with Comorbid and Cardiovascular Conditions.

International journal of chronic obstructive pulmonary disease·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

Role of Airwave Oscillometry in Patients with Combined Fibrosis-Emphysema Syndrome (CPFE) with Preserved FEV1/FVC Ratio.

Diagnostics (Basel, Switzerland)·2026
Same author

Respiratory health in a changing environment: environment-adaptive therapies and revised dosing strategies.

Expert review of respiratory medicine·2026
Same author

Centripetal Axonal Transport as a Gateway to the CNS for Veterinary Antiparasitics: Bypassing the Blood-Brain Barrier, Clinical Impact in Vulnerable Age Groups, and the Potential Facilitating Role of PFAS.

Journal of toxicology·2026

Related Experiment Video

Updated: Mar 30, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K

Current and Emerging Biologic Therapies for Severe Asthma.

Mario Cazzola1, Maria Gabriella Matera2, Josuel Ora3

  • 1Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome 'Tor Vergata', Via Montpellier, 1, 00133, Rome, Italy. mario.cazzola@uniroma2.it.

Drugs
|March 28, 2026
PubMed
Summary

Current biologics for severe asthma improve outcomes, but new therapies are needed for difficult-to-treat types. Next-generation treatments target upstream alarmins and multiple pathways for personalized medicine.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

876

Related Experiment Videos

Last Updated: Mar 30, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.7K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

41.7K
Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome
09:06

Microbioreactor-Based Production of Anchorage-Dependent Mesenchymal Stromal Cells Primed for Acute Respiratory Distress Syndrome

Published on: December 12, 2025

876

Area of Science:

  • Pulmonology
  • Immunology
  • Pharmacology

Background:

  • Severe asthma is a complex, heterogeneous condition with persistent symptoms and exacerbations.
  • Current approved monoclonal antibodies target IgE, IL-5, IL-4 receptor α, and TSLP, showing efficacy in reducing exacerbations and corticosteroid use.
  • Despite advances, limitations exist for specific asthma phenotypes and airway remodeling.

Purpose of the Study:

  • To review the current landscape of approved biologics for severe asthma.
  • To discuss the rationale and emerging strategies for next-generation therapies.
  • To highlight future directions for precision-targeted treatment in severe asthma.

Main Methods:

  • Review of approved monoclonal antibodies and their targets (IgE, IL-5, IL-4Rα, TSLP).
  • Analysis of clinical efficacy, safety profiles, and predictors of response.
  • Exploration of emerging therapeutic strategies targeting alarmins, cytokine pathways, and B cells.

Main Results:

  • Approved biologics offer substantial benefits in exacerbation reduction, lung function, and quality of life.
  • Response predictors include blood eosinophil counts, fractional exhaled nitric oxide, and phenotype-specific biomarkers.
  • Next-generation therapies aim to address unmet needs in type 2-low and refractory asthma phenotypes.

Conclusions:

  • Biologics have transformed severe asthma management, but heterogeneity necessitates further innovation.
  • Emerging strategies, including multi-target agents and upstream alarmin inhibitors, promise improved outcomes.
  • Biomarker-guided personalized therapy represents the future direction for severe asthma treatment.